Implantable cardiac defibrillator leads dysfunction after LVAD implantation

Affiliation auteurs!!!! Error affiliation !!!!
TitreImplantable cardiac defibrillator leads dysfunction after LVAD implantation
Type de publicationJournal Article
Year of Publication2020
AuteursGaland V, Leclercq C, Bourenane H, Boule S, Vincentelli A, Maury P, Mondoly P, Picard F, Welte N, Kindo M, Cardi T, Pasquie J-L, Gaudard P, Gourraud J-B, Probst V, Defaye P, Boignard A, Para M, Algalarrondo V, Pelce E, Gariboldi V, Pozzi M, Obadia J-F, Anselme F, Litzler P-Y, Blanchart K, Babatasi G, Garnier F, Bielefeld M, Hamon D, Lellouche N, Bourguignon T, Pierre B, Eschalier R, D'Ostrevy N, Varlet E, Marijon E, Blangy H, Sadoul N, Flecher E, Martins RP
JournalPACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
Volume43
Pagination1309-1317
Date PublishedNOV
Type of ArticleArticle
ISSN0147-8389
Mots-clésImplantable cardioverter defibrillator, lead parameters dysfunction, Left ventricular assist device
Résumé

Background Implantable cardioverter-defibrillator (ICD) lead dysfunction has been reported after left ventricular assist device (LVAD) implantation in limited single-center studies. We aimed at describing and characterizing the incidence of ICD lead parameters dysfunction after LVAD implantation. Methods Among the 652 patients enrolled in the ASSIST-ICD study, only patients with an ICD prior to LVAD were included (n = 401). ICD lead parameters dysfunction following LVAD implantation is defined as follows: (a) >50% decrease in sensing threshold, (b) pacing lead impedance increase/decrease by >100 omega, and (c) >50% increase in pacing threshold. Results One hundred twenty-two patients with an ICD prior to LVAD had available ICD interrogation reports prior and after LVAD. A total of 67 (55%) patients exhibited at least one significant lead dysfunction: 17 (15%) exhibited >50% decrease in right ventricular (RV) sensing, 51 (42%) had >100 omega increase/decrease in RV pacing impedance, and 24 (20%) experienced >50% increase in RV pacing threshold. A total of 52 patients experienced ventricular arrhythmia during follow-up and all were successfully detected and treated by the device. All lead dysfunction could be managed conservatively. Conclusion More than 50% of LVAD-recipients may experience >1 significant change in lead parameters but none had severe clinical consequences.

DOI10.1111/pace.14004